Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: A multicentre MITO retrospective study
Articolo
Data di Pubblicazione:
2017
Abstract:
To evaluate the impact of tertiary cytoreductive surgery (TCS) on survival in recurrent epithelial ovarian cancer (EOC), and to determine predictors of complete cytoreduction.
METHODS:
A multi-institutional retrospective study was conducted within the MITO Group on a 5-year observation period.
RESULTS:
A total of 103 EOC patients with a ≥6month treatment-free interval (TFI) undergoing TCS were included. Complete cytoreduction was achieved in 71 patients (68.9%), with severe post-operative complications in 9.7%, and no cases of mortality within 60days from surgery. Multivariate analysis identified the complete tertiary cytoreduction as the most potent predictor of survival followed by FIGO stage I-II at initial diagnosis, exclusive retroperitoneal recurrence, and TCS performed ≥3years after primary diagnosis. Patients with complete tertiary cytoreduction had a significantly longer overall survival (median OS: 43months, 95% CI 31-58) compared to those with residual tumor (median OS: 33months, 95% CI 28-46; p<0.001). After multivariate adjustment the presence of a single lesion and good (ECOG 0) performance status were the only significant predictors of complete surgical cytoreduction.
METHODS:
A multi-institutional retrospective study was conducted within the MITO Group on a 5-year observation period.
RESULTS:
A total of 103 EOC patients with a ≥6month treatment-free interval (TFI) undergoing TCS were included. Complete cytoreduction was achieved in 71 patients (68.9%), with severe post-operative complications in 9.7%, and no cases of mortality within 60days from surgery. Multivariate analysis identified the complete tertiary cytoreduction as the most potent predictor of survival followed by FIGO stage I-II at initial diagnosis, exclusive retroperitoneal recurrence, and TCS performed ≥3years after primary diagnosis. Patients with complete tertiary cytoreduction had a significantly longer overall survival (median OS: 43months, 95% CI 31-58) compared to those with residual tumor (median OS: 33months, 95% CI 28-46; p<0.001). After multivariate adjustment the presence of a single lesion and good (ECOG 0) performance status were the only significant predictors of complete surgical cytoreduction.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Cytoreductive surgery; Quality of surgery; Recurrent ovarian cancer; Oncology; Obstetrics and Gynecology
Elenco autori:
Falcone, F.; Scambia, G.; Benedetti Panici, P.; Signorelli, M.; Cormio, G.; Giorda, G.; Bogliolo, S.; Marinaccio, M.; Ghezzi, F.; Rabaiotti, E.; Breda, E.; Casella, G.; Fanfani, Francesco; Di Donato, V.; Leone Roberti Maggiore, U.; Greggi, S.
Link alla scheda completa:
Pubblicato in: